Madhav Dhodapkar

Dr. Madhav Dhodapkar is a distinguished Professor in the Department of Hematology and Oncology at the University of Washington School of Medicine, with joint appointments as an Academic Professor in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center in Seattle. His clinical practice is based at Fred Hutchinson Cancer Center-South Lake Union.

His educational background includes:

• MBBS from All India Institute of Medical Sciences
• Residency in Internal Medicine at St. Louis University Hospital
• Fellowship in Hematology at Mayo Clinic School of Medicine
• Board Certification in Hematology and Oncology from the American Board of Internal Medicine

Dr. Dhodapkar's research focuses on the immune pathogenesis of multiple myeloma, with particular expertise in tumor microenvironment, T-cell dysfunction, and novel immunotherapeutic approaches for hematological malignancies. His work bridges basic immunology with clinical applications in myeloma treatment.

Analysis of his recent publications (2019-2025) reveals a strong emphasis on multiple myeloma immunology, with increasing focus on immune checkpoint inhibitors, CAR T-cell therapy, and the metabolic regulation of anti-tumor immunity. His research combines advanced techniques including single-cell sequencing, CyTOF, and CITE-seq to characterize the myeloma immune microenvironment.

Dr. Dhodapkar is actively involved in developing clinical practice guidelines and conducting randomized clinical trials for myeloma treatment, serving on international consensus panels including the International Myeloma Society/International Myeloma Working Group.

His clinical expertise centers on multiple myeloma, with a focus on translating immunological discoveries into novel therapeutic approaches for this hematological malignancy. He maintains active clinical practice while leading translational research initiatives at Fred Hutchinson Cancer Center.